Publications by authors named "N Chaput"
Cancer immunotherapy, including immune checkpoint inhibitors, chimeric antigen receptor T-cell therapy and bispecific antibodies, has led to major improvements in the treatment of a wide range of hematologic malignancies and solid tumors. However, age-mediated immune system modifications, known as immunosenescence, may preclude its efficacy in elderly patients. In this review, we assessed the efficacy of these different cancer immunotherapies in elderly patients compared to young patients to revisit the concept of immunosenescence from a therapeutic perspective.
View Article and Find Full Text PDFImmune checkpoint inhibitors (ICI)-based combinations have become the standard first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). Despite significant improvements in survival and the achievement of sustained long-term responses, a subset of patients remains refractory to ICI, and most will eventually develop resistance. Thus, identifying predictive biomarkers for ICI efficacy and resistance is essential for optimizing therapeutic strategies.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the significance of metabolic tumor volume (tMTV) in patients with advanced non-small cell lung cancer (NSCLC) undergoing immune checkpoint blockade (ICB) therapy, using 18F-FDG-PET/CT scans.
- It involved 518 patients across multiple institutions and found that those with high tMTV had poorer overall survival when treated with ICBs alone compared to those with low tMTV.
- The research suggests that high tMTV is associated with increased systemic inflammation and genomic instability, making it a potential biomarker for determining treatment strategies in NSCLC patients with positive PD-L1 expression.
Article Synopsis
- Circulating proteomes can reveal the body's response to diseases like COVID-19 and treatments like tocilizumab, which is used to mitigate severe symptoms.
- In a study involving 28 hospitalized COVID-19 patients treated with tocilizumab, researchers collected serum samples to analyze changes in protein levels before and after treatment and assessed patient outcomes for 30 days.
- Findings indicated that specific proteins related to the complement system and Fc-epsilon receptor signaling could predict treatment success and mortality, where high complement activation linked to worse outcomes and certain signaling pathways showed lower mortality rates.
Purpose: With liquid biopsy's widespread adoption in oncology, an increased number of clonal hematopoiesis-associated mutations (CHm) have been identified in patients with solid tumors. However, its impact on patient outcomes remains unclear. This study aimed to analyze and describe CHm in a cohort of phase I patients.
View Article and Find Full Text PDF